• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

世界卫生组织基于基因的抗COVID-19疫苗接种后不良反应因果关系评估算法:陷阱与改进建议

The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.

作者信息

Bellavite Paolo, Donzelli Alberto, Isidoro Ciro

机构信息

Independent Researcher, 37134 Verona, Italy.

Foundation Allineare Sanità e Salute, via Ricordi 4, 20131 Milano, Italy.

出版信息

J Clin Med. 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291.

DOI:10.3390/jcm13237291
PMID:39685749
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11642405/
Abstract

Clarifying and differentiating the causes of diseases is an essential step in any clinical activity, but it takes on particular relevance and complexity in the case that arise following vaccinations. The WHO has proposed a protocol that uses a list of specific questions about vaccine-related adverse events and an algorithm for making a judgement. Here, we analyze and discuss the important limitations of this protocol when applied to the new genetic-based anti-COVID-19 vaccines, particularly once dealing with rare and unexpected pathological events. The main controversial aspects concern: (a) the prevailing consideration of other possible causes; (b) the biological plausibility and the choice of an appropriate time window to consider adverse effects possibly caused by vaccines; (c) the reference to scientific literature, which may be very limited and often controversial in early stages of introducing new vaccines because of the short period of observation; (d) the final classification of the algorithm into only three classes, which leaves ample space for the "indeterminate" category. Failure to address these issues may lead to distorted pharmacovigilance reports with significant consequences on the benefit/harm assessment. In anticipation of possible future pandemics managed with new vaccines, the WHO algorithm needs to be revised with appropriate protocols for monitoring and evaluation of adverse effects that take into account the novel mechanism of action and real-world epidemiological data.

摘要

明确和区分疾病原因是任何临床活动的关键步骤,但在疫苗接种后出现的病例中,这一过程具有特殊的相关性和复杂性。世界卫生组织(WHO)提出了一项方案,该方案使用一系列关于疫苗相关不良事件的特定问题清单以及一种判断算法。在此,我们分析并讨论该方案在应用于新型基因新冠疫苗时的重要局限性,尤其是在处理罕见和意外的病理事件时。主要存在争议的方面包括:(a)对其他可能原因的普遍考量;(b)生物学合理性以及考虑疫苗可能导致的不良反应的合适时间窗的选择;(c)对科学文献的参考,由于观察期较短,在引入新疫苗的早期阶段,科学文献可能非常有限且往往存在争议;(d)算法最终仅分为三类,这为“不确定”类别留出了很大空间。未能解决这些问题可能导致药物警戒报告失真,对利弊评估产生重大影响。鉴于未来可能会使用新疫苗应对大流行,WHO算法需要通过适当的不良反应监测和评估方案进行修订,这些方案应考虑到新的作用机制和实际流行病学数据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/61d8488fe210/jcm-13-07291-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/ff2a8b5a33dd/jcm-13-07291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/be1991224523/jcm-13-07291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/61d8488fe210/jcm-13-07291-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/ff2a8b5a33dd/jcm-13-07291-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/be1991224523/jcm-13-07291-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4d18/11642405/61d8488fe210/jcm-13-07291-g003.jpg

相似文献

1
The WHO Algorithm for Causality Assessment of Adverse Effects Following Immunization with Genetic-Based Anti-COVID-19 Vaccines: Pitfalls and Suggestions for Improvement.世界卫生组织基于基因的抗COVID-19疫苗接种后不良反应因果关系评估算法:陷阱与改进建议
J Clin Med. 2024 Nov 30;13(23):7291. doi: 10.3390/jcm13237291.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Causality assessment of adverse events following immunization: the problem of multifactorial pathology.疫苗接种后不良反应的因果关系评估:多因素病理学问题。
F1000Res. 2020 Mar 9;9:170. doi: 10.12688/f1000research.22600.2. eCollection 2020.
4
Serious neurological adverse events following immunization against SARS-CoV-2: a narrative review of the literature.2019冠状病毒病疫苗接种后的严重神经系统不良事件:文献综述
Ther Adv Drug Saf. 2023 May 21;14:20420986231165674. doi: 10.1177/20420986231165674. eCollection 2023.
5
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.免疫接种后安全性监测:疫苗不良事件报告系统(VAERS)——美国,1991 - 2001年
MMWR Surveill Summ. 2003 Jan 24;52(1):1-24.
6
Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use.疫苗不良反应(AEFI)个体不良事件因果关系评估:全球使用的世卫组织工具。
Vaccine. 2013 Oct 17;31(44):5041-6. doi: 10.1016/j.vaccine.2013.08.087. Epub 2013 Sep 8.
7
Adverse events following immunization: is this time for the use of WHO causality assessment?免疫接种后的不良事件:现在是使用世界卫生组织因果关系评估的时候了吗?
Expert Rev Vaccines. 2015 May;14(5):625-7. doi: 10.1586/14760584.2015.1029460. Epub 2015 Mar 25.
8
Application of the revised WHO causality assessment protocol for adverse events following immunization in India.经修订的世界卫生组织免疫接种后不良事件因果关系评估方案在印度的应用。
Vaccine. 2017 Jul 24;35(33):4197-4202. doi: 10.1016/j.vaccine.2017.06.027. Epub 2017 Jun 22.
9
Causality assessment of serious and severe adverse events following immunization in India: a 4-year practical experience.印度疫苗接种后严重和严重不良事件因果关系评估:4 年实践经验。
Expert Rev Vaccines. 2018 Jun;17(6):555-562. doi: 10.1080/14760584.2018.1484285. Epub 2018 Jun 11.
10
Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.接种 COVID-19 疫苗后的毛细血管渗漏综合征:来自欧洲药物警戒数据库 Eudravigilance 的数据。
Front Immunol. 2022 Sep 13;13:956825. doi: 10.3389/fimmu.2022.956825. eCollection 2022.

本文引用的文献

1
Active Surveillance for Safety Monitoring of XBB.1.5-Containing COVID-19 mRNA Vaccines in Korea.韩国使用 XBB.1.5 含新冠 mRNA 疫苗的主动监测安全性监测。
J Korean Med Sci. 2024 Nov 11;39(43):e309. doi: 10.3346/jkms.2024.39.e309.
2
Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance.研究药物的获益-风险概况:从自发报告系统到用于药物警戒的真实世界数据。
Methods Mol Biol. 2025;2834:333-349. doi: 10.1007/978-1-0716-4003-6_16.
3
Does the COVID-19 Vaccination Reduce the Risk to Transmit SARS-CoV-2 to Others?
新冠病毒疫苗接种是否降低了将 SARS-CoV-2 传播给他人的风险?
Adv Exp Med Biol. 2024;1457:247-264. doi: 10.1007/978-3-031-61939-7_14.
4
COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.新冠病毒疫苗对医护人员预防有症状感染和严重感染有效:一项临床综述。
Vaccine X. 2024 Aug 5;20:100546. doi: 10.1016/j.jvacx.2024.100546. eCollection 2024 Oct.
5
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.辉瑞 Comirnaty COVID-19 mRNA 疫苗获益-风险评估的 Brighton 协作组织标准化模板:关键考虑因素。
Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27.
6
Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies.新冠病毒感染后和疫苗相关的神经并发症具有相同的临床特征和抗 ACE2 抗体阳性。
Front Immunol. 2024 Aug 1;15:1398028. doi: 10.3389/fimmu.2024.1398028. eCollection 2024.
7
Severe acquired hemophilia A associated with COVID-19 vaccination: A case report and literature review.严重获得性血友病 A 与 COVID-19 疫苗接种相关:病例报告及文献复习。
Medicine (Baltimore). 2024 Aug 2;103(31):e39166. doi: 10.1097/MD.0000000000039166.
8
A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province.意大利某省新冠疫苗接种期间全因死亡情况的批判性分析
Microorganisms. 2024 Jun 30;12(7):1343. doi: 10.3390/microorganisms12071343.
9
Long-term risk of autoimmune diseases after mRNA-based SARS-CoV2 vaccination in a Korean, nationwide, population-based cohort study.mRNA 基于的 SARS-CoV-2 疫苗接种后在韩国全国基于人群队列研究中的自身免疫性疾病的长期风险。
Nat Commun. 2024 Jul 23;15(1):6181. doi: 10.1038/s41467-024-50656-8.
10
A Causality Assessment Framework for COVID-19 Vaccines and Adverse Events at the COVID-19 Vaccine Safety Research Center.用于 COVID-19 疫苗和 COVID-19 疫苗安全研究中心不良事件的因果关系评估框架。
J Korean Med Sci. 2024 Jul 8;39(26):e220. doi: 10.3346/jkms.2024.39.e220.